PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

mTOR is an important therapeutic target in many types of cancers. In melanoma, the mTOR nonsynonymous mutation rate is up to 10.4%. However, mTOR inhibitors have shown limited effects in clinical trials of melanoma. Because mTOR mutations are distributed, not selecting patients with specific mTOR mu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Wu, Xiaowen, Yu, Jiayi, Yan, Junya, Dai, Jie, Si, Lu, Chi, Zhihong, Sheng, Xinan, Cui, Chuanliang, Ma, Meng, Tang, Huan, Xu, Tianxiao, Yu, Huan, Kong, Yan, Guo, Jun
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989792/
https://ncbi.nlm.nih.gov/pubmed/29708815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1435221
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados